Quality of life and functioning of Hispanic patients with Major Depressive Disorder before and after treatment
- PMID: 28826087
- PMCID: PMC5626642
- DOI: 10.1016/j.jad.2017.08.031
Quality of life and functioning of Hispanic patients with Major Depressive Disorder before and after treatment
Abstract
Background: Similar rates of remission from Major Depressive Disorder (MDD) have been documented between ethnic groups in response to antidepressant treatment. However, ethnic differences in functional outcomes, including patient-reported quality of life (QOL) and functioning, have not been well-characterized. We compared symptomatic and functional outcomes of antidepressant treatment in Hispanic and non-Hispanic patients with MDD.
Methods: We analyzed 2280 nonpsychotic treatment-seeking adults with MDD who received citalopram monotherapy in Level 1 of the Sequenced Treatment Alternatives to Relieve Depression study. All subjects (239 Hispanic, 2041 non-Hispanic) completed QOL, functioning, and depressive symptom severity measures at entry and exit.
Results: Hispanic participants had significantly worse QOL scores at entry and exit (p < 0.01). However, after controlling for baseline QOL, there was no difference between Hispanic and non-Hispanic patients' QOL at exit (p = 0.21). There were no significant between-group differences at entry or at exit for depressive symptom severity or functioning. Both groups had significant improvements in depressive symptom severity, QOL, and functioning from entry to exit (all p values < 0.01). Patients with private insurance had lower depressive symptom severity, greater QOL, and better functioning at exit compared to patients without private insurance.
Limitations: This study was a retrospective data analysis, and the Hispanic group was relatively small compared to the non-Hispanic group.
Conclusions: Hispanic and non-Hispanic participants with MDD had similar responses to antidepressant treatment as measured by depressive symptom severity scores, quality of life, and functioning. Nevertheless, Hispanic patients reported significantly worse quality of life at entry.
Trial registration: ClinicalTrials.gov NCT00021528.
Keywords: Functioning; Hispanic; Latino/a; Major Depressive Disorder; Quality of Life; SSRI.
Copyright © 2017 Elsevier B.V. All rights reserved.
Conflict of interest statement
Similar articles
-
Quality of Life, Functioning, and Depressive Symptom Severity in Older Adults With Major Depressive Disorder Treated With Citalopram in the STAR*D Study.J Clin Psychiatry. 2017 Jul;78(7):897-903. doi: 10.4088/JCP.16m11335. J Clin Psychiatry. 2017. PMID: 28858443 Clinical Trial.
-
Quality of Life and Functioning in Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder After Treatment With Citalopram Monotherapy.Clin Neuropharmacol. 2017 Jan/Feb;40(1):16-23. doi: 10.1097/WNF.0000000000000190. Clin Neuropharmacol. 2017. PMID: 27764051
-
Patient-reported outcomes of quality of life, functioning, and depressive symptom severity in major depressive disorder comorbid with panic disorder before and after SSRI treatment in the star*d trial.Depress Anxiety. 2014 Aug;31(8):707-16. doi: 10.1002/da.22152. Epub 2013 Jul 16. Depress Anxiety. 2014. PMID: 23861180 Free PMC article. Clinical Trial.
-
Major Depressive Disorder in Patients With Doctoral Degrees: Patient-reported Depressive Symptom Severity, Functioning, and Quality of Life Before and After Initial Treatment in the STAR*D Study.J Psychiatr Pract. 2017 Sep;23(5):328-341. doi: 10.1097/PRA.0000000000000251. J Psychiatr Pract. 2017. PMID: 28961662 Clinical Trial.
-
Major depressive disorder.Nat Rev Dis Primers. 2016 Sep 15;2:16065. doi: 10.1038/nrdp.2016.65. Nat Rev Dis Primers. 2016. PMID: 27629598 Review.
Cited by
-
Prevalence and Associated Factors for Depressive Symptomatology in Chinese Adults During COVID-19 Epidemic.Front Psychol. 2020 Dec 23;11:616723. doi: 10.3389/fpsyg.2020.616723. eCollection 2020. Front Psychol. 2020. PMID: 33424729 Free PMC article.
-
Health Related Quality of Life in Major Depressive Disorder: evolution in time and factors associated.Actas Esp Psiquiatr. 2022 Jan;50(1):15-26. Epub 2022 Jan 1. Actas Esp Psiquiatr. 2022. PMID: 35103294 Free PMC article.
-
Specific aspects of religious involvement protect against depressive symptoms among immigrant versus U.S.-born, Hispanic older adults.Aging Ment Health. 2024 Apr;28(4):658-666. doi: 10.1080/13607863.2023.2265848. Epub 2023 Oct 9. Aging Ment Health. 2024. PMID: 37811722 Free PMC article.
-
The Cost Effectiveness of Mental Health Treatment in the Lifetime of Older Adults with HIV in New York City: A Markov Approach.Pharmacoecon Open. 2021 Jun;5(2):221-236. doi: 10.1007/s41669-020-00238-3. Epub 2020 Nov 9. Pharmacoecon Open. 2021. PMID: 33165825 Free PMC article.
References
-
- Beck AT, Guth D, Steer RA, Ball R. Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for Primary Care. Behav Res Ther. 1997;35:785–791. - PubMed
-
- Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry. 1994;151:979–986. - PubMed
-
- Chokka P, Legault M. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial. Depress Anxiety. 2008;25:E173–181. - PubMed
-
- Cohen J. Statistical power analysis for the behavioral sciences. 2. Hillsdale, New Jersey: 1988.
-
- Demyttenaere K, Andersen HF, Reines EH. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. Int Clin Psychopharmacol. 2008;23:276–286. - PubMed
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical